Piqray vs. Kisqali
Are Piqray and Kisqali the Same Thing?
Piqray (alpelisib) and Kisqali (ribociclib) are kinase inhibitors used to treat metastatic breast cancer.
Piqray is used in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
Kisqali is used in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Side effects of Piqray and Kisqali that are similar include diarrhea, rash, nausea, fatigue, decreased appetite, inflammation of the mouth and lips, vomiting, hair loss, abdominal pain, swelling of extremities, fever, urinary tract infection (UTI), headache, and itching.
Side effects of Piqray that are different from Kisqali include weight loss, indigestion, dry nose, changes in taste, dry skin, prolonged aPTT, and laboratory abnormalities (increased or decreased blood sugar, increased creatinine, decreased lymphocyte count, increased GGT, increased ALT, decreased hemoglobin, increased lipase, and decreased calcium).
Side effects of Kisqali that are different from Piqray include low white blood cell count (neutropenia, leukopenia), constipation, back pain, anemia, low levels of lymphocytes in the blood (lymphopenia), insomnia, and shortness of breath.
Piqray may interact with CYP3A4 inducers, BCRP inhibitors, warfarin, and acid reducing agents.
Kisqali may interact with ritonavir, boceprevir, clarithromycin, conivaptan, grapefruit juice, pomegranates or pomegranate juice, indinavir, azole antifungals, lopinavir/ritonavir, nefazodone, nelfinavir, saquinavir, phenytoin, rifampin, carbamazepine, St John's wort, alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, amiodarone, disopyramide, procainamide, quinidine, and sotalol.
What Are Possible Side Effects of Piqray?
Side effects of Piqray include:
- diarrhea
- rash
- nausea
- fatigue
- decreased appetite
- inflammation of the mouth and lips
- vomiting
- weight loss
- hair loss
- abdominal pain
- indigestion
- swelling of extremities
- fever
- dry nose
- urinary tract infection (UTI)
- changes in taste
- headache
- itching
- dry skin
- prolonged aPTT
- and laboratory abnormalities (increased or decreased blood sugar
- increased creatinine
- decreased lymphocyte count
- increased GGT
- increased ALT
- decreased hemoglobin
- increased lipase
- and decreased calcium)
What Are Possible Side Effects of Kisqali?
Common side effects of Kisqali include:
- low white blood cell count (neutropenia, leukopenia),
- nausea,
- fatigue,
- diarrhea,
- hair loss,
- vomiting,
- constipation,
- headache,
- back pain,
- urinary tract infection,
- anemia,
- low levels of lymphocytes in the blood (lymphopenia),
- decreased appetite,
- insomnia,
- shortness of breath,
- swelling and sores inside the mouth,
- abdominal pain,
- rash,
- itching,
- fever, and
- swelling of extremities.
What Is Piqray?
Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
What Is Kisqali?
Kisqali (ribociclib) is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
What Drugs Interact With Piqray?
Piqray may interact with CYP3A4 inducers, BCRP inhibitors, warfarin, and acid reducing agents. Tell your doctor all medications and supplements you use. Piqray is not recommended for use during pregnancy; it may harm a fetus. Piqray is used in combination with fulvestrant, which may also harm a fetus. It is unknown if Piqray passes into breast milk. Because of the potential for serious adverse reactions in the breastfed child, breastfeeding is not recommended during treatment with Piqray and for 1 week after the last dose.
What Drugs Interact With Kisqali?
Kisqali may interact with ritonavir, boceprevir, clarithromycin, conivaptan, grapefruit juice, pomegranates or pomegranate juice, indinavir, azole andtifungals, lopinavir/ritonavir, nefazodone, nelfinavir, saquinavir, phenytoin, rifampin, carbamazepine, St John's wort, alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, amiodarone, disopyramide, procainamide, quinidine, and sotalol. Tell your doctor all medications and supplements you use.
How Should Piqray be Taken?
The recommended dose of Piqray is 300 mg (two 15 0 mg tablets) taken orally once daily with food.
How Should Kisqali be Taken?
The recommended starting dose of Kisqali is 600 mg orally (three 200 mg tablets) taken once daily with or without food for 21 consecutive days followed by 7 days off treatment.
